Optimization of PK/PD Target Attainment for Meropenem in Critically Ill Patients With Sepsis
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 116
- Primary Endpoint
- Risk factors for target non attainment
Study Overview
Brief Summary
WP1.1. PK/PD target attainment: Plasma exposure, Excretion via urine & ELF exposure; WP1.2. Predictive dosing algorithm; WP1.3. ECMO subset
Detailed Description
First, the investigators will document exposure to meropenem in plasma and epithelial lining fluid. Moreover excretion in urine will be documented.
Second, the investigators will try to identify risk factors for not attaining PK/PD target. Based on significant predictors for target non attainment a predictive dosing algorithm will be constructed.
Finally in a small subset of ECMO patients PK exposure will be explored.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Severe sepsis or septic shock
- •Admitted to an ICU ward
- •Treated with meropenem
Exclusion Criteria
- •eGFR(CKD-EPI) < 70ml/min/1.73m²
- •Renal replacement therapy
- •Pregnancy
- •DNR code 1-3
Outcomes
Primary Outcomes
Risk factors for target non attainment
Time Frame: on day of sampling
risk factors will be assessed by comparing patients who attain target vs. those who don't
Secondary Outcomes
No secondary outcomes reported
Investigators
Matthias Gijsen
PharmD
Universitaire Ziekenhuizen KU Leuven